(Q43812577)

27 November 2017

Effects of risperidone on information processing and attention in first-episode schizophrenia (English)

1 reference

27 November 2017

1 reference

1 reference

1 reference

information processing

1 reference

K S Hong

1

1 reference

27 November 2017

J G Kim

2

1 reference

27 November 2017

H J Koh

3

1 reference

27 November 2017

M S Koo

4

1 reference

27 November 2017

J H Kim

5

1 reference

27 November 2017

D Lee

6

1 reference

27 November 2017

E Kim

7

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

27 November 2017

Schizophrenia Research

1 reference

27 November 2017

53

1 reference

27 November 2017

1-2

1 reference

27 November 2017

7-16

1 reference

Information processing and attention dysfunctions in schizophrenia

27 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

Reaction time and prognosis in acute schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

Relationships between changes in symptom ratings, neurophysiological test performance and quality of life in schizophrenic patients treated with clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

What are the functional consequences of neurocognitive deficits in schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

Cognitive effects of beta-adrenergic antagonists after single doses: pharmacokinetics and pharmacodynamics of propranolol, atenolol, lorazepam, and placebo.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

The effect of neuroleptics on cognitive and psychomotor function

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

Generalized cognitive deficits in schizophrenia: a study of first-episode patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

Information processing and attentional functioning in the developmental course of schizophrenic disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

Information processing and social competence in chronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

Memory deficits and anticholinergic levels in chronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

Cognitive improvement in schizophrenia with novel antipsychotic medications

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

The cognitive efficacy of atypical antipsychotics in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

The effect of risperidone on cognition in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

Seroquel and cognitive improvement in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

Neuroleptic effects on neuropsychological test performance in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

Effects of short-term outcome and clinical improvement on reaction time in acute schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900167-0

7 January 2021

10.1016/S0920-9964(01)00167-0

Identifiers

DOI

1 reference

27 November 2017

1 reference